Search clinical trials for: JAK2
Total 59 results
-
Bristol-Myers SquibbTerminated
-
Shanghai Zhongshan HospitalUnknownPortal Hypertension | Myeloproliferative Neoplasm | Gastroesophageal Varices | Portal Caver CavernomaChina
-
Matthew J KosterEli Lilly and CompanyCompleted
-
Assiut UniversityUnknownDetection of PCM1-JAK2 Fusion Gene by FISH in the Two Types of t-MDS/AML and Relationship Between PCM1-JAK2 Fusion Gene and Cumulative Dose, Dose Intensity
-
Karyopharm Therapeutics IncActive, not recruitingMyelofibrosisSpain, China, Poland, United States, France, Greece, Italy
-
Philipps University Marburg Medical CenterCompletedCOVID | ARDS, HumanGermany
-
CelgeneCompletedMyelofibrosis | Myeloid Metaplasia | Myelofibrosis With Myeloid MetaplasiaUnited States, Italy, United Kingdom, Austria, Spain
-
M.D. Anderson Cancer CenterCephalonCompleted
-
PharmaEssentiaMedpace, Inc.; EPS International; Brightech InternationalActive, not recruitingEssential ThrombocythemiaUnited States, Canada, Korea, Republic of, China, Hong Kong, Singapore, Taiwan, Japan
-
Novartis PharmaceuticalsCompletedIdiopathic Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia-Vera MyelofibrosisUnited Kingdom, Ireland, Germany, Italy, France
-
University of Michigan Rogel Cancer CenterTerminatedLymphoproliferative Disorders | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Lymphoma, T-Cell, Cutaneous | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Lymphoma, T-Cell, PeripheralUnited States
-
Swiss Group for Clinical Cancer ResearchCompletedPrimary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative NeoplasmSwitzerland
-
William ShomaliIncyte CorporationRecruitingEosinophilia | Hypereosinophilic Syndrome | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Splenomegaly | Hepatomegaly | Chronic Eosinophilic Leukemia, Not Otherwise Specified | JAK2 Gene Mutation | BCR-JAK2 Fusion Protein Expression | Blasts 20 Percent or Less of Peripheral Blood White... and other conditionsUnited States
-
French Innovative Leukemia OrganisationCompleted
-
Shanghai Zhongshan HospitalUnknownMyeloproliferative Neoplasm | Gastroesophageal Varices | JAK2 Mutation
-
PharmaEssentiaNot yet recruitingPolycythemia Vera | Myeloproliferative Neoplasm
-
National Cancer Institute (NCI)Not yet recruitingKSHV Inflammatory Cytokine Syndrome (KICS) | Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman DiseaseUnited States
-
Karyopharm Therapeutics IncNot yet recruitingMyelofibrosis | Moderate Thrombocytopenia
-
CelgeneRecruitingPrimary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera MyelofibrosisFrance, Belgium, Austria, Spain, Australia, Canada, Japan, United States, Korea, Republic of, Romania, Israel, Italy, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Colombia, Argentina, Chile and more
-
Ronald HoffmanNational Cancer Institute (NCI); Myeloproliferative Disorders-Research ConsortiumTerminated
-
Assistance Publique - Hôpitaux de ParisCompletedMyeloproliferative DisordersFrance
-
NYU Langone HealthWithdrawnCancer | Hematological MalignancyUnited States
-
Fox Chase Cancer CenterNot yet recruitingPrimary Myelofibrosis | Polycythemia Vera | Chronic Myelomonocytic Leukemia | Essential Thrombocytosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States
-
M.D. Anderson Cancer CenterRecruitingPrimary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential ThrombocythemiaUnited States
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Centre Hospitalier Annecy GenevoisCompleted
-
S*BIOCompletedMyelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous LeukemiaUnited States
-
Ascentage Pharma Group Inc.WithdrawnMyelofibrosisUnited States
-
Mansoura UniversityCompletedResponse Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK ExpressionEgypt
-
National Jewish HealthCompletedChronic Beryllium Disease (CBD) | Beryllium Sensitization (BeS)United States
-
Ottawa Hospital Research InstituteCanadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR)... and other collaboratorsActive, not recruitingPrimary Myelofibrosis | Venous Thromboembolism (VTE) | Polycythemia Vera (PV) | Essential Thrombocythemia (ET) | JAK2 Mutation | Myeloproliferative Neoplasm (MPN)Canada
-
Novartis PharmaceuticalsTerminatedPrimary Myelofibrosis | Post-Polycythemia Vera | Post-Essential ThrombocytopeniaUnited States
-
Eli Lilly and CompanyCompleted
-
Stichting Hemato-Oncologie voor Volwassenen NederlandCTI BioPharma; Dutch Cancer SocietyActive, not recruitingMyelofibrosisNetherlands, Belgium
-
Tanta UniversityCompletedRheumatoid ArthritisEgypt
-
Royal Free Hospital NHS Foundation TrustEnrolling by invitationMyeloproliferative Neoplasm | Splanchnic Vein Thrombosis | JAK2 V617United Kingdom
-
AstraZenecaTerminatedSolid MalignanciesUnited States
-
Ronald HoffmanNational Cancer Institute (NCI); Myeloproliferative Disorders-Research ConsortiumUnknownPolycythemia Vera | Essential Thrombocythemia | MyelofibrosisUnited States
-
S*BIOCompletedMyeloproliferative Disorders | Polycythemia Vera | Essential Thrombocythemia | MyelofibrosisUnited States, Australia
-
Samsung Medical CenterCompletedPrimary Mediastinal Large B-cell Lymphoma | Relapsed or Refractory Hodgkin LymphomaKorea, Republic of
-
University Medical Centre LjubljanaCompleted
-
Incyte CorporationCompleted
-
University Hospital, BrestRecruitingPolycythemia Vera | Essential Thrombocythemia | High-risk Patients | Prefibrotic/Early Primary Myelofibrosis | JAK2 V617FFrance
-
The Lymphoma Academic Research OrganisationNovartisCompletedHodgkin's LymphomaFrance, Belgium
-
National Cancer Institute (NCI)Recruiting
-
Postgraduate Institute of Medical Education and...RecruitingPortal Vein Thrombosis | Anticoagulants and Bleeding Disorders | Hepatic Vein Thromboses | Hepatic Venous Outflow Obstruction | Portal Hypertension, Noncirrhotic | Portal Vein Occlusion | Portal Vein Embolism | JAK2 Mutation | CALR Gene Mutation | Prothrombin G20210AIndia
-
Actuate Therapeutics Inc.Completed
-
National Cancer Institute (NCI)Not yet recruiting
-
University of UtahNational Cancer Institute (NCI)TerminatedObstructive Sleep Apnea Syndrome | Polycythemia Vera | Essential Thrombocythemia | CALR Gene Mutation | JAK2 Gene Mutation | MPL Gene MutationUnited States